Merck & Company Inc (MRK) - Total Assets
Based on the latest financial reports, Merck & Company Inc (MRK) holds total assets worth $129.55 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Merck & Company Inc's book value for net asset value and shareholders' equity analysis.
Merck & Company Inc - Total Assets Trend (1985–2024)
This chart illustrates how Merck & Company Inc's total assets have evolved over time, based on quarterly financial data.
Merck & Company Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Merck & Company Inc's total assets of $129.55 Billion consist of 33.1% current assets and 66.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $13.24 Billion | 11.3% |
| Accounts Receivable | $10.28 Billion | 8.8% |
| Inventory | $6.11 Billion | 5.2% |
| Property, Plant & Equipment | $25.15 Billion | 21.5% |
| Intangible Assets | $16.37 Billion | 14.0% |
| Goodwill | $21.67 Billion | 18.5% |
Asset Composition Trend (1985–2024)
This chart illustrates how Merck & Company Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MRK market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Merck & Company Inc's current assets represent 33.1% of total assets in 2024, a decrease from 47.1% in 1985.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2024, down from 17.2% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 1.0% in 1985.
- Asset Diversification: The largest asset category is property, plant & equipment at 21.5% of total assets.
Merck & Company Inc Competitors by Total Assets
Key competitors of Merck & Company Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.07 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$110.95 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $115.57 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$208.73 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥13.11 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
Merck & Company Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.66 | 1.36 | 1.02 |
| Quick Ratio | 1.44 | 1.15 | 0.81 |
| Cash Ratio | 0.63 | 0.49 | 0.00 |
| Working Capital | $18.93 Billion | $10.78 Billion | $437.00 Million |
Merck & Company Inc - Advanced Valuation Insights
This section examines the relationship between Merck & Company Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.81 |
| Latest Market Cap to Assets Ratio | 2.38 |
| Asset Growth Rate (YoY) | 9.8% |
| Total Assets | $117.11 Billion |
| Market Capitalization | $278.38 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Merck & Company Inc's assets at a significant premium (2.38x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Merck & Company Inc's assets grew by 9.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Merck & Company Inc (1985–2024)
The table below shows the annual total assets of Merck & Company Inc from 1985 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $117.11 Billion | +9.78% |
| 2023-12-31 | $106.67 Billion | -2.28% |
| 2022-12-31 | $109.16 Billion | +3.28% |
| 2021-12-31 | $105.69 Billion | +15.40% |
| 2020-12-31 | $91.59 Billion | +8.52% |
| 2019-12-31 | $84.40 Billion | +2.13% |
| 2018-12-31 | $82.64 Billion | -5.96% |
| 2017-12-31 | $87.87 Billion | -7.87% |
| 2016-12-31 | $95.38 Billion | -6.20% |
| 2015-12-31 | $101.68 Billion | +3.58% |
| 2014-12-31 | $98.17 Billion | -7.08% |
| 2013-12-31 | $105.64 Billion | -0.46% |
| 2012-12-31 | $106.13 Billion | +0.96% |
| 2011-12-31 | $105.13 Billion | -0.62% |
| 2010-12-31 | $105.78 Billion | -5.82% |
| 2009-12-31 | $112.31 Billion | +137.98% |
| 2008-12-31 | $47.20 Billion | -2.39% |
| 2007-12-31 | $48.35 Billion | +8.48% |
| 2006-12-31 | $44.57 Billion | -0.62% |
| 2005-12-31 | $44.85 Billion | +5.34% |
| 2004-12-31 | $42.57 Billion | +4.89% |
| 2003-12-31 | $40.59 Billion | -14.66% |
| 2002-12-31 | $47.56 Billion | +8.04% |
| 2001-12-31 | $44.02 Billion | +10.30% |
| 2000-12-31 | $39.91 Billion | +12.00% |
| 1999-12-31 | $35.63 Billion | +11.87% |
| 1998-12-31 | $31.85 Billion | +23.77% |
| 1997-12-31 | $25.74 Billion | +5.94% |
| 1996-12-31 | $24.29 Billion | +1.94% |
| 1995-12-31 | $23.83 Billion | +9.04% |
| 1994-12-31 | $21.86 Billion | +9.68% |
| 1993-12-31 | $19.93 Billion | +79.75% |
| 1992-12-31 | $11.09 Billion | +16.71% |
| 1991-12-31 | $9.50 Billion | +18.29% |
| 1990-12-31 | $8.03 Billion | +18.84% |
| 1989-12-31 | $6.76 Billion | +10.27% |
| 1988-12-31 | $6.13 Billion | +7.88% |
| 1987-12-31 | $5.68 Billion | +11.26% |
| 1986-12-31 | $5.11 Billion | +4.14% |
| 1985-12-31 | $4.90 Billion | -- |
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also pr… Read more